M ABL G*
ABL kinase domain gene sequencing
chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL), allogeneic bone marrow transplantation, minimal residual disease (MRD), molecular remission, Gleevec® resistance
Quantitative reverse transcriptase PCR (RT-PCR), Semi-nested PCR, Bi-directional DNA sequencing
Testing is performed at MolecularMD of Portland, Oregon pursuant to patents.
10.0 mL (min. 9.0 mL) peripheral blood in EDTA
2.0 mL (min. 1.0 mL) bone marrow in EDTA
Ship peripheral blood and bone marrow at refrigerated temperature.
Please notify us if specimen is to arrive after 1 p.m. on Friday or Saturday.
Specimen > 48 hours old;
Stored or shipped at incorrect temperature;
Insufficient specimen volume
ABL Kinase domain mutation(s) detected and characterized / not detected
MolecularMD has designed and validated bi-directional Sanger sequencing assays to identify mutations in the p210 and p190 transcripts of the BCR-ABL1 fusion gene. Our assay spans an extended region including the kinase and SH2-SH3 regulatory domains and is able to detect over 40 amino acid substitutions including the T315I mutation.
Gleevec® is a registered trademark of the Novartis Pharmaceuticals Corporation.